Active, not recruitingPhase 3NCT06373731

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Studying Medullary sponge kidney

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stealth BioTherapeutics Inc.
Principal Investigator
Rekha Sathyanarayana
Stealth BioTherapeutics
Intervention
Elamipretide(drug)
Enrollment
313 target
Eligibility
55 years · All sexes
Timeline
20242027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06373731 on ClinicalTrials.gov

Other trials for Medullary sponge kidney

Additional recruiting or active studies for the same condition.

See all trials for Medullary sponge kidney

← Back to all trials